• Bystander memory T cells and IMiD/checkpoint therapy in multiple myeloma: A dangerous tango? 

      Sponaas, Anne-Marit; Waage, Anders; Vandsemb, Esten; Misund, Kristine; Børset, Magne; Sundan, Anders; Slørdahl, Tobias Schmidt; Standal, Therese (Peer reviewed; Journal article, 2021)
      In this review article we discuss the role of the memory T cells in multiple myeloma (MM) and how they may influence immune responses in patients that received immunomodulating drugs and check point therapy
    • Chemical, Physical and Biological Triggers of Evolutionary Sonserved Bcl-xL-Mediated Apoptosis 

      Ianevski, Aleksandr; Kulesskiy, Evgeny; Krpina, Klara; Lou, Guofeng; Aman, Yahyah; Bugai, Andrii; Aasumets, Koit; Akimov, Yevhen; Bulanova, Daria; Gildemann, Kiira; Arutyunyan, Albert F.; Susova, Olga Yu.; Zhuze, Alexei L.; Ji, Ping; Wang, Wei; Holien, Toril; Bugge, Marit; Zusinaite, Eva; Oksenych, Valentyn; Lysvand, Hilde; Gerhold, Joachim M.; Bjørås, Magnar; Johansen, Pål; Waage, Anders; Heckman, Caroline A.; Fang, Evandro Fei; Kainov, Denis (Journal article; Peer reviewed, 2020)
      Background: The evidence that pan-Bcl-2 or Bcl-xL-specific inhibitors prematurely kill virus-infected or RNA/DNA-transfected cells provides rationale for investigating these apoptotic inducers further. We hypothesized that ...
    • Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade 

      Yang, Rui; Elsaadi, Samah; Misund, Kristine; Abdollahi, Pegah; Vandsemb, Esten; Moen, Siv Helen; Kusnierczyk, Anna; Slupphaug, Geir; Standal, Therese; Waage, Anders; Slørdahl, Tobias Schmidt; Rø, Torstein Baade; Rustad, Even Holth; Sundan, Anders; Hay, Carl; Cooper, Zachary; Schuller, Alwin G.; Woessner, Richard; Borodowski, Alexandra; Menu, Eline; Børset, Magne; Sponaas, Anne-Marit (Peer reviewed; Journal article, 2020)
      Background PD1/PDL1-directed therapies have been unsuccessful for multiple myeloma (MM), an incurable cancer of plasma cells in the bone marrow (BM). Therefore, other immune checkpoints such as extracellular adenosine and ...
    • Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients 

      Rampa, Christoph Samuel; Tian, Erming; Våtsveen, Thea Kristin; Buene, Glenn; Slørdahl, Tobias Schmidt; Børset, Magne; Waage, Anders; Sundan, Anders (Journal article; Peer reviewed, 2014)
      Background Hepatocyte growth factor (HGF) is a pleiotropic cytokine which can lead to cancer cell proliferation, migration and metastasis. In multiple myeloma (MM) patients it is an abundant component of the bone marrow. ...
    • Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982–2017 

      Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2020)
      Population‐based studies from high‐quality nationwide cancer registries provide an important alternative to clinical trials in the assessment of the impact of modern myeloma treatment. Based on data from the Cancer Registry ...
    • Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial 

      Sonja Zweegman, Zweegman; Claudia A M Stege, A; Haukås, Einar; Schjesvold, Fredrik H; Mark-David Levin, Levin; Waage, Anders; Rineke B L Leys, B; Saskia K Klein, K; Szatkowski, Damian Lukasz; Per Axelsson, Axelsson; Trung Hieu Do, Hieu; Dorota Knut-Bojanowska, Knut-Bojanowska; Ellen van der Spek, van; Asta Svirskaite, Svirskaite; Anja Klostergaard, Klostergaard; Morten Salomo, Salomo; Celine Blimark, Blimark; Paula F Ypma, F; Ulf-Henrik Mellqvist, Mellqvist; Pino J Poddighe, J; Marian Stevens-Kroef, Stevens-Kroef; Niels W C J van de Donk, W; Pieter Sonneveld, Sonneveld; Markus Hansson, Hansson; Bronno van der Holt, van; Niels Abildgaard, Abildgaard (Peer reviewed; Journal article, 2020)
    • Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report 

      Murray, David L.; Puig, Noemi; Kristinsson, Sigurður Y.; Usmani, Saad; Dispenzieri, Angela; Bianchi, Giada; Kumar, Shaji; Chng, Wee Joo; Hajek, Roman; Paiva, Bruno; Waage, Anders; Rajkumar, S. Vincent; Durie, Brian (Peer reviewed; Journal article, 2021)
      Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect ...
    • Patterns of previous and secondary malignancies in patients with multiple myeloma 

      Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2021)
      Objectives: In contrast to secondary primary malignancies (SPM) following multiple myeloma (MM), less is known about previous malignancies. We therefore conducted a population-based study to assess the patterns of previous ...
    • Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia 

      Zatula, Alexey; Dikic, Aida; Mulder, Teska Celine; Sharma, Animesh; Vågbø, Cathrine Broberg; Sousa, Mirta; Waage, Anders; Slupphaug, Geir (Peer reviewed; Journal article, 2017)
      Plasma cell leukemia is a rare and aggressive plasma cell neoplasm that may either originate de novo (primary PCL) or by leukemic transformation of multiple myeloma (MM) to secondary PCL (sPCL). The prognosis of sPCL is ...
    • Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials 

      Palumbo, Antonio; Waage, Anders; Hulin, Cyrille; Beksac, M; Zweegman, Sonja; Gay, Francesca; Gimsing, Peter; Leleu, X; Wijermans, P; Sucak, G; Pezzatti, S; Juliusson, Gunnar; Pegourie, B; Schaafsma, Marije; Galli, M; Turesson, Ingemar; Kolb, B; van der Holt, B; Baldi, I; Rolke, Jürgen; Ciccone, G; Wetterwald, M; Lokhorst, H; Boccadoro, Mario; Rodon, P; Sonneveld, Pieter (Journal article; Peer reviewed, 2013)
      Treatment with melphalan-prednisone-thalidomide improves the outcome of patients with multiple myeloma and is now considered a standard of care for patients not eligible for transplantation. However, this treatment is a ...
    • Why do myeloma patients have bone disease? A historical perspective. 

      Børset, Magne; Sundan, Anders; Waage, Anders; Standal, Therese (Peer reviewed; Journal article, 2019)
      The question of how myeloma cells cause destruction of skeletal tissue has interested scientists for many years, and knowledge in this field has developed in parallel with the understanding of physiological bone remodeling. ...